Christopher Uhde's questions to Alvotech SA (ALVO) leadership • Q2 2025
Question
Christopher Uhde of SEB inquired about Alvotech's confidence in its full-year 2025 guidance, the potential for further growth from the Cymlandi (Humira biosimilar) Qualant channel in the U.S., and whether the company plans to issue press releases on FDA inspection outcomes for its late-stage pipeline candidates.
Answer
CFO Linda Jónsdóttir stated that while H1 was strong, the company is not changing its guidance due to expected revenue lumpiness, with Q3 being soft and Q4 being much stronger. CCO Anil Okay added that the Qualant channel business is expected to continue, but the focus is on value over volume. CEO Róbert Wessman explained that FDA inspections are a normal part of business and the company will inform the market upon product approvals rather than after each inspection.